primary liver cancer
Conditions
Interventions
Treatment group:hepatic arterial infusion chemotherapy combined with caririzumab and ramvaritinib
Sponsors
Shenzhen Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the clinical diagnostic criteria of China's 2019 Edition of Norms for the Diagnosis and Treatment of Primary Liver Cancer; 2. Patient aged >= 18 years; 3. Barcelona Clinic Liver Cancer (BCLC) stage C; Combined with portal vein tumor thrombus; 4. According to RECIST v1.1, there was at least one measurable or evaluable lesion; 5. Expected survival time >=12 weeks; 6. The physical state score (ECOG PS score) was 0-2 according to the Eastern Cancer Cooperative Group; 7. Child-Pugh grade A to B; 8. After evaluation, the investigators planned to administer hepatic arterial infusion chemotherapy combined with carrilizumab and Lunvatinib; 9. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Received live attenuated vaccine within 4 weeks prior to enrollment or during the study period; 2. Active, known, or suspected autoimmune diseases; 3. Known history of primary immunodeficiency; 4. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation; 5. Pregnant or breastfeeding patients; 6. Untreated persons with acute or chronic active hepatitis B or C. In the case of monitoring the virus copy number of patients receiving antiviral therapy, doctors will determine whether patients are eligible for inclusion according to their individual conditions; 7. Uncontrolled concurrent diseases, including but not limited to: (1) HIV-infected persons (HIV-antibody positive); (2) Severe infection in the active stage or with poor clinical control; (3) Evidence of serious or uncontrolled systemic disease (e.g., severe mental, neurological, epilepsy or dementia, unstable or uncompensable respiratory, cardiovascular, liver or kidney disease, uncontrolled hypertension (i.e., CTCAE level 2 hypertension after medication); (4) Patients with active bleeding or new thrombotic diseases who are taking therapeutic amounts of anticoagulant drugs or have bleeding tendencies; (5) Abnormal coagulation function (INR>1.5xULN, APTT>1.5xULN); 8. Patients currently undergoing clinical trials of other drugs; 9. Other patients deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood;Liver function;Renal function;Blood coagulation function;Hepatitis B surface antigen;HBV quantification;Alpha-fetoprotein;Electrocardiogram;Chest computed tomography;Abdominal CTA or MRI;Thyroid function; | — |
Countries
China
Contacts
Public ContactCai Qingxian
Shenzhen Third People's Hospital
Outcome results
None listed